Sign Up to Receive Your Personalised Learning Resources
Start Learning
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia
Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients
Current and future considerations for the use of immune checkpoint inhibitors in non-small cell lung cancer
Top 3 highlights from EONS16: Virpi Sulosaari
Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer
Immune checkpoint inhibitors in solid tumours: Optimizing outcomes through multidisciplinary collaboration
ZUMA-23 study of axicabtagene ciloleucel as first-line therapy in large B-cell lymphoma: Jason Westin, EHA 2023
The evolving treatment landscape in relapsed/refractory multiple myeloma
PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
Sign up to view Favourites, Keep Notes and Track CME Credits
Favourites
Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
View
Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations
View
Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements
View
The role of RNA-based next-generation sequencing in identifying pathogenic gene fusions
View
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
View
Is HER2 targeting on the horizon in urothelial carcinoma?
View
Arnulf Stenzl, EAU23: Latest developments in urological oncology
View
Guideline-based treatment of recurrent/metastatic cervical cancer
View
Ryan Sullivan, AACR 2023: The STARBOARD phase III trial, encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma
View
Highlights in breast cancer – KEYNOTE-756, Checkmate-7FL, TOPION-Breast01, monarchE: Sara Tolaney, ESMO 2023
View